{
  "abstract": "The median overall survival (OS) for patients with recurrent or metastatic cervical cancer after progression on first-line therapy is only 5–12 months. We retrospectively reviewed four patients who received modified induction–maintenance therapy. All of the patients achieved clinical benefit to varying degrees, with one attaining progression-free survival (PFS) of over 58 months and an OS of 86 months. However, these findings should be interpreted with caution and warrant validation in larger prospective studies.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Cancer Biotherapy Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Peking University Cancer Hospital Yunnan"
  ],
  "article_type": "case report",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yiqing Duan"
    },
    {
      "affs": [
        0
      ],
      "name": "Dan Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Qian Huang"
    },
    {
      "affs": [
        0
      ],
      "name": "Jianghan Man"
    },
    {
      "affs": [
        0
      ],
      "name": "Li Li"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuanbo Xue"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/axyt4fz0yaqk4.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1961384",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724560/?tool=EBI",
  "id": "axyt4fz0yaqk4",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1961384/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Case Report"
    ],
    [
      "openalex",
      "2729|Endometrial and Cervical Cancer Treatments"
    ]
  ],
  "openalex": "W7222931987",
  "pdf_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1961384/pdf",
  "pmcid": "PMC13724560",
  "pmid": "42973612",
  "published": "2026-10-19",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/axyt4fz0yaqk4.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1961384",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1961384/full"
    },
    {
      "first_seen": "2026-11-03T15:20:50Z",
      "native_id": "PMC:PMC13724560",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13724560"
    },
    {
      "first_seen": "2026-11-04T12:23:06Z",
      "native_id": "PMC13724560",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fonc.2026.1961384"
    },
    {
      "first_seen": "2026-11-04T15:20:48Z",
      "native_id": "MED:42973612",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42973612"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2729|Endometrial and Cervical Cancer Treatments",
      "subfield": "reproductive-child"
    }
  ],
  "title": "Case Report: Prolonged survival with short-course triplet induction and dual maintenance in recurrent/metastatic cervical cancer",
  "title_text": "Case Report: Prolonged survival with short-course triplet induction and dual maintenance in recurrent/metastatic cervical cancer",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T12:21:00Z",
  "url": "https://research.draconitic.com/paper/axyt4fz0yaqk4",
  "venue": "Frontiers in Oncology",
  "versions": []
}